News & Updates
Filter by Specialty:
Dog owners ward off asthma against risk allele carriers
Among individuals carrying the 17q12-21 asthma-risk variant rs2305480, owning a dog appears to exert a protective effect against persistent wheeze, a recent study has found.
Dog owners ward off asthma against risk allele carriers
29 Oct 2022
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
28 Oct 2022
COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
Use of molnupiravir or nirmatrelvir/ritonavir in high-risk patients with mild-to-moderate COVID-19 is associated with reduced in-hospital mortality, reduced hospital admissions or readmissions, and potential healthcare cost savings, according to a real-world retrospective cohort study led by researchers from the Chinese University of Hong Kong and the University of Hong Kong.
COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
27 Oct 2022
Smell, taste dysfunction post-COVID-19: will these persist?
Olfactory and gustatory** loss/alterations are common COVID-19 symptoms, but recovery is expected in most patients within the first 3 months. However, these dysfunctions may persist in some individuals, according to a reconstructed meta-analysis from Singapore.
Smell, taste dysfunction post-COVID-19: will these persist?
26 Oct 2022
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
23 Oct 2022
Mitokine levels predict COPD outcomes
In patients with chronic obstructive pulmonary disease (COPD), mitokine levels are elevated and are associated with important clinical outcomes such as disease exacerbation and exercise capacity, a recent study has found.
Mitokine levels predict COPD outcomes
19 Oct 2022
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
16 Oct 2022
Pemetrexed-based chemo boosts survival in NSCLC
As an add-on to gefitinib monotherapy, pemetrexed-based chemotherapy improves survival outcomes in nonsmall cell lung cancer (NSCLC) patients harbouring EGFR mutations, a recent study has found.
